Cite
HARVARD Citation
Kavanaugh, A. et al. (2017). Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Annals of the rheumatic diseases. 76 (6), pp. 1009-1019. [Online].